86 related articles for article (PubMed ID: 23702590)
1. Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.
Flores MV; Corbau RG; Guionaud S
Antivir Ther; 2013; 18(6):775-84. PubMed ID: 23702590
[TBL] [Abstract][Full Text] [Related]
2. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
[TBL] [Abstract][Full Text] [Related]
3. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys.
Xu L; Zuch CL; Lin YS; Modi NB; Lum BL
Cancer Chemother Pharmacol; 2008 Apr; 61(4):607-14. PubMed ID: 17549476
[TBL] [Abstract][Full Text] [Related]
5. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Vercauteren K; Van Den Eede N; Mesalam AA; Belouzard S; Catanese MT; Bankwitz D; Wong-Staal F; Cortese R; Dubuisson J; Rice CM; Pietschmann T; Leroux-Roels G; Nicosia A; Meuleman P
Hepatology; 2014 Nov; 60(5):1508-18. PubMed ID: 24797654
[TBL] [Abstract][Full Text] [Related]
6. Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor.
Régeard M; Trotard M; Lepère C; Gripon P; Le Seyec J
J Viral Hepat; 2008 Dec; 15(12):865-70. PubMed ID: 19087225
[TBL] [Abstract][Full Text] [Related]
7. The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters.
Rhainds D; Brodeur M; Lapointe J; Charpentier D; Falstrault L; Brissette L
Biochemistry; 2003 Jun; 42(24):7527-38. PubMed ID: 12809509
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
9. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination.
Zahid MN; Turek M; Xiao F; Thi VL; Guérin M; Fofana I; Bachellier P; Thompson J; Delang L; Neyts J; Bankwitz D; Pietschmann T; Dreux M; Cosset FL; Grunert F; Baumert TF; Zeisel MB
Hepatology; 2013 Feb; 57(2):492-504. PubMed ID: 23081796
[TBL] [Abstract][Full Text] [Related]
10. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
Nnane IP; Xu Z; Zhou H; Davis HM
Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
[TBL] [Abstract][Full Text] [Related]
11. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
13. The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
Perrault M; Pécheur EI
Biochem J; 2009 Oct; 423(3):303-14. PubMed ID: 19807698
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys.
Kakkar T; Ma M; Zhuang Y; Patton A; Hu Z; Mounho B
Pharm Res; 2007 Oct; 24(10):1910-8. PubMed ID: 17520181
[TBL] [Abstract][Full Text] [Related]
15. Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
Komocsar WJ; Blackbourne JL; Halstead CA; Winstead CJ; Wierda D
J Immunotoxicol; 2016; 13(1):7-19. PubMed ID: 25585959
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
[TBL] [Abstract][Full Text] [Related]
17. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
[TBL] [Abstract][Full Text] [Related]
18. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
